Literature DB >> 11091939

A nicotinic cholinergic agonist (GTS-21) and eyeblink classical conditioning: acquisition, retention, and relearning in older rabbits.

D S Woodruff-Pak1, J T Green, C Coleman-Valencia, J T Pak.   

Abstract

Previously we demonstrated that GTS-21, a nicotinic cholinergic agonist, ameliorated eyeblink classical conditioning deficits in older rabbits. The present experiment was undertaken to replicate and extend these results by examining the effects of GTS-21 on retention and relearning. Retired breeder rabbits received 15 daily injections of 0.5 mg/kg GTS 21 (n = 8) or sterile saline vehicle (n = 8) during acquisition training, and no further injections occurred. Acquisition of conditioned responses (CRs) was significantly better in GTS-21-treated rabbits. During the first tone-alone retention session in week 6 of the experiment, rabbits initially treated with GTS-21 produced significantly more CRs than vehicle-treated rabbits. There were no group differences in retention at the 13-week retest. Differences in relearning were in the predicted direction but did not attain statistical significance. Results indicate that treatment with GTS-21 ameliorates learning beyond the period when the drug is actually administered.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11091939     DOI: 10.1080/036107300750015723

Source DB:  PubMed          Journal:  Exp Aging Res        ISSN: 0361-073X            Impact factor:   1.645


  8 in total

Review 1.  α7 nicotinic ACh receptors as a ligand-gated source of Ca(2+) ions: the search for a Ca(2+) optimum.

Authors:  Victor V Uteshev
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

Review 2.  Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization.

Authors:  Edward D Levin; F Joseph McClernon; Amir H Rezvani
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

Review 3.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

Review 4.  Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.

Authors:  Edward D Levin; Amir H Rezvani
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

5.  Cannabis use disrupts eyeblink conditioning: evidence for cannabinoid modulation of cerebellar-dependent learning.

Authors:  Patrick D Skosnik; Chad R Edwards; Brian F O'Donnell; Ashley Steffen; Joseph E Steinmetz; William P Hetrick
Journal:  Neuropsychopharmacology       Date:  2007-07-18       Impact factor: 7.853

Review 6.  Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking.

Authors:  Enrique L M Ochoa; Jose Lasalde-Dominicci
Journal:  Cell Mol Neurobiol       Date:  2007-08       Impact factor: 5.046

7.  Improved Cholinergic Transmission is Detrimental to Behavioural Plasticity in Honeybees (Apis mellifera).

Authors:  David Guez; Hong Zhu; Shao-Wu Zhang
Journal:  Biology (Basel)       Date:  2012-10-16

Review 8.  The current agonists and positive allosteric modulators of α7 nAChR for CNS indications in clinical trials.

Authors:  Taoyi Yang; Ting Xiao; Qi Sun; Kewei Wang
Journal:  Acta Pharm Sin B       Date:  2017-10-16       Impact factor: 11.413

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.